Monitor for Nasdaq listing approval and closing conditions (PIPE, regulatory). The CVRs provide optional upside on legacy assets but are likely to expire worthless. Post-merger, the combined company (OBX) will be a clinical-stage biotech focused on Obsidian's TIL therapy (OBX-115).
Price Chart
Executive Summary
Galera Therapeutics (GRTX) is merging with Obsidian Therapeutics via a reverse merger into a new parent company (Gazelle Parent, Inc., expected to trade as OBX on Nasdaq). Galera stockholders will receive shares of Parent common stock and CVRs tied to legacy assets (tilarginine, GC4419, GC4711). A concurrent $350M PIPE financing will close alongside the merger. Galera stockholders will own approximately 1.29% of the combined company (assuming $10M Galera valuation and $(2.00)M net cash), while Obsidian holders and PIPE investors will own ~53.46% and ~45.25%, respectively. The merger is expected to close in Q3 2026.
Key Facts
- Galera and Obsidian will merge into a new parent company (Gazelle Parent, Inc.), expected to trade on Nasdaq as OBX.
- Galera stockholders will receive shares of Parent common stock (estimated exchange ratio ~0.7515 after 1:200 reverse split) plus CVRs for legacy assets.
- A concurrent $350.0M PIPE financing is a condition to closing.
- Galera is valued at $10.0M (subject to net cash adjustment); Obsidian at $413.5M.
- Pre-closing Galera security holders (excluding PIPE investors) are expected to own ~1.29% of the combined company.
- Galera stockholders of record will receive CVRs: 80% of net proceeds from tilarginine (5-year term) and 95% from Supportive-Care Product Divestiture (10-year term).
- Galera common stock will cease trading on OTCQB upon closing.
- The merger has been approved by written consent of Galera stockholders holding a majority of outstanding shares.
Financial Impact
Galera valued at $10.0M (subject to net cash adjustment); Obsidian valued at $413.5M. Combined company to receive $350.0M in PIPE proceeds. Galera stockholders will own ~1.29% of combined entity.
Risk Factors
- Merger may not close if Nasdaq listing or PIPE conditions are not met.
- Galera stockholders face massive dilution (~1.29% ownership of combined company).
- CVRs may expire worthless if legacy assets are not monetized.
- Combined company will require additional capital post-merger.
- Obsidian has a going concern qualification and significant cash burn ($132.5M projected for FY2026).
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4/A Filing (Primary) | 0001193125-26-281076 |
| Document: d117787dex21.htm | 0001193125-26-281076 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | SC 13G | $13.22 | awaiting T+20 | — | $14.08 (+6.51%) |
Sep 10, 2026 6w ago | EFFECT | $17.16 $12.24 | ▼ −28.67% | ▼ −30.80% | $14.08 (−17.95%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.08 (−58.59%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.08 (−58.59%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.08 (−58.59%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.08 (−58.59%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.08 (−58.59%) |
Aug 3, 2026 12w ago | 3 | $34.00 $17.04 | ▼ −49.88% | ▼ −48.64% | $14.08 (−58.59%) |
Aug 3, 2026 12w ago | 8-K | $34.00 $17.04 | ▲ +49.88% | ▲ +48.64% | $14.08 (+58.59%) |
Jul 6, 2026 16w ago | EFFECT | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers